Active Filter(s):
Details:
The company develops topical and oral drugs based on proprietary small molecules that inhibit an ion channel designated TRPV3. These drugs are intended for the treatment of various dermatological diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: GIBF2
Deal Size: $8.0 million Upfront Cash: Undisclosed
Deal Type: Financing September 19, 2022